Sign In
Last checked at 
19 Jan 2009 08:24
ο»Ώ
Β
Hutchison China MediTech Limited ("Chi-Med")Β
(AIM: HCM)
Director's Shareholding
London:Β Monday,Β 19Β JanuaryΒ 2009:Β Chi-MedΒ was informedΒ on 16 January 2009Β that Mr Michael Howell, Independent Non-executive Director of Chi-Med, purchasedΒ 100,000 ordinary shares of US$1.00Β each in Chi-Med (the "Shares") at a price ofΒ 42.5pΒ each onΒ 15Β JanuaryΒ 2009.
Following this purchase, Mr Howell is beneficially interested inΒ 143,000Β Shares, representing approximatelyΒ 0.3%Β of the current issued share capital of Chi-Med.
Ends
Enquiries
|
Chi-Med Christian Hogg, CEO |
Telephone: +852 2121 8200 |
|
Citigate Dewe Rogerson Anthony Carlisle David Dible |
Telephone: +44 (0) 20 7638 9571 +44 (0) 7973 611 888 +44 (0) 7967 566 919 |
About Chi-Med
Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily inΒ ChinaΒ and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.
Β
Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.
Follow the stocks
